Merck said total worldwide sales for Q2 2024 were $16,112 million, up 7% from Q2 2023 $15,035 million. Excluding the impact of foreign exchange, growth was 11%.

1. 01

   Merck said total worldwide sales for Q2 2024 were $16,112 million, up 7% from Q2 2023 $15,035 million. Excluding the impact of foreign exchange, growth was 11%.

2. 02

   The company said KEYTRUDA sales for Q2 were $7,270 million, up 16% from $6,271 million a year earlier. Excluding the impact of foreign exchange, sales grew 21%. The company cited increased global uptake of earlier-stage indications as a driver of growth.

3. 03

   Merck said GAAP EPS for Q2 2024 was $2.14 and non-GAAP EPS was $2.28, compared with per-share losses of $(2.35) and $(2.06), respectively, in Q2 2023. The company said Q2 2023 included a charge of $4.02 per share for the acquisition of Prometheus.

4. 04

   Merck said it now expects full-year 2024 sales of $63.4 billion to $64.4 billion, compared with its prior outlook of $63.1 billion to $64.3 billion, and non-GAAP EPS of $7.94 to $8.04, compared with $8.53 to $8.65 previously. The company said the outlook reflects a 1-time charge of about $1.3 billion ($0.51 per share) for the EyeBio acquisition.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.